Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Table 4

Five most commonly prescribed first-line treatment regimens, overall and by country.

Treatment	Overall ()		UK ()		Spain ()		Germany ()		France ()
	n	%	n	%	n	%	n	%	n	%
Doxorubicin	330	40.9	94	47.2	72	35.5	107	52.5	57	28.4
Doxorubicin + ifosfamide^a	153	19.0	31	15.6	31	15.3	34	16.7	57	28.4
Docetaxel + gemcitabine	70	8.7	16	8.0	21	10.3	27	13.2	^b	^b
Paclitaxel	34	4.2	^b	^b	13	6.4	8	3.9	10	5.0
Ifosfamide^a	33	4.1	15	7.5	10	4.9	^b	^b	^b	^b
Dacarbazine + doxorubicin + ifosfamide	^b	^b	11	5.5	^b	^b	^b	^b	^b	^b
Dacarbazine + ifosfamide^a	^b	^b	^b	^b	^b	^b	6	2.9	^b	^b
Epirubicin + ifosfamide^a	^b	^b	^b	^b	^b	^b	^b	^b	17	8.5
Trabectedin	^b	^b	^b	^b	^b	^b	^b	^b	11	5.5

NA: not applicable; UK: United Kingdom; ^amesna was always coadministered with ifosfamide; ^bmay have been observed in the overall or country-specific sample but was not among the five most commonly prescribed first-line regimens.